Vaxart, Inc. (VXRT)
NASDAQ: VXRT · Real-Time Price · USD
0.3576
+0.0106 (3.05%)
Dec 22, 2025, 4:00 PM EST - Market closed
Vaxart Revenue
Vaxart had revenue of $39.73M in the quarter ending June 30, 2025, with 520.68% growth. This brings the company's revenue in the last twelve months to $80.72M, up 479.58% year-over-year. In the year 2024, Vaxart had annual revenue of $28.70M with 288.94% growth.
Revenue (ttm)
$80.72M
Revenue Growth
+479.58%
P/S Ratio
0.55
Revenue / Employee
$1,411,467
Employees
105
Market Cap
85.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.70M | 21.32M | 288.94% |
| Dec 31, 2023 | 7.38M | 7.27M | 6,796.26% |
| Dec 31, 2022 | 107.00K | -785.00K | -88.00% |
| Dec 31, 2021 | 892.00K | -3.15M | -77.95% |
| Dec 31, 2020 | 4.05M | -5.82M | -58.97% |
| Dec 31, 2019 | 9.86M | 5.70M | 137.12% |
| Dec 31, 2018 | 4.16M | -1.68M | -28.77% |
| Dec 31, 2017 | 5.84M | -3.06M | -34.39% |
| Jun 30, 2017 | 8.90M | -400.00K | -4.30% |
| Jun 30, 2016 | 9.30M | -15.30M | -62.20% |
| Jun 30, 2015 | 24.60M | -44.10M | -64.19% |
| Jun 30, 2014 | 68.70M | 35.10M | 104.46% |
| Jun 30, 2013 | 33.60M | 13.20M | 64.71% |
| Jun 30, 2012 | 20.40M | 5.56M | 37.48% |
| Dec 31, 2011 | 14.84M | 2.34M | 18.70% |
| Jun 30, 2011 | 12.50M | -22.51M | -64.29% |
| Dec 25, 2010 | 35.01M | 24.52M | 233.73% |
| Dec 26, 2009 | 10.49M | - | - |
| Dec 27, 2008 | - | - | - |
| Dec 29, 2007 | - | - | - |
| Dec 30, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VXRT News
- 4 weeks ago - Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript - Seeking Alpha
- 5 weeks ago - Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Vaxart to Host Upcoming Conference Calls - GlobeNewsWire
- 6 weeks ago - Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program - PRNewsWire
- 6 weeks ago - Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program - PRNewsWire
- 2 months ago - Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 - GlobeNewsWire
- 3 months ago - Vaxart Appoints W. Mark Watson as Lead Independent Director - GlobeNewsWire
- 3 months ago - Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate - GlobeNewsWire